[1]Karlsson L, Mesterton J, Tepie MF, et al. Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control[J]. Arch Osteoporos, 2017,12:81-83. doi: 10.1007/s11657-017-0375-7. [2]Boschitsch EP, Durchschlag E, Dimai HP. Age-related prevalence of osteoporosis and fragility fractures: real-world data from an Austrian Menopause and Osteoporosis Clinic[J]. Climacteric, 2017,20:157-163.doi: 10.1080/13697137.2017.1282452. [3]Sun Y, Guo HH, Guo DD, et al. Divergence of genes encoding CITED1 and CITED2 in blunt snout bream (megalobrama amblycephala) and their transcriptional responses to hypoxia[J]. Front Physiol, 2018,9:186-188.doi: 10.3389/fphys.2018.00186. [4]Li X, Chen X, Zhou W, et al. Effect of melatonin on neuronal differentiation requires CBP/p300-mediated acetylation of histone H3 lysine 14[J]. Neuroscience, 2017,364:45-59.doi: 10.1016/j.neuroscience.2017.07.064. [5]Sauer M, Schuldner M, Hoffmann N, et al. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells[J]. Oncogene, 2017,36:933-941. doi: 10.1038/onc.2016.259. [6]Ichise T, Yoshida N, Ichise H. CBP/p300 antagonises EGFR-Ras-Erk signalling and suppresses increased Ras-Erk signalling-induced tumour formation in mice[J]. J Pathol, 2019,249:39-51.doi: 10.1002/path.5279. [7]Olzscha H, Fedorov O, Kessler BM, et al. CBP/p300 bromodomains regulate amyloid-like protein aggregation upon aberrant lysine acetylation[J]. Cell Chem Biol, 2017,24:9-23.doi: 10.1016/j.chembiol.2016.11.009. [8]Castillo J, Wu E, Lowe C, et al. CBP/p300 drives the differentiation of regulatory T cells through transcriptional and non-transcriptional mechanisms[J]. Cancer Res, 2019,79:3916-3927. doi: 10.1158/0008-5472.CAN-18-3622. [9]Xia E, Wang Y, Bhandari A, et al. CITED1 gene promotes proliferation, migration and invasion in papillary thyroid cancer[J]. Oncol Lett, 2018,16:105-112. doi: 10.3892/ol.2018.8653. [10]Li H, Guan H, Guo Y, et al. CITED1 promotes proliferation of papillary thyroid cancer cells via the regulation of p21 and p27[J]. Cell Biosci,2018,8:57-60. doi: 10.1186/s13578-018-0256-9. [11]Namwanje M, Liu L, Chan M, et al. The depot-specific and essential roles of CBP/p300 in regulating adipose plasticity[J]. J Endocrinol,2019,240:257-269. doi: 10.1530/JOE-18-0361. [12]Xu B, Li Q, Chen N, et al. The LIM protein ajuba recruits DBC1 and CBP/p300 to acetylate ERalpha and enhances ERalpha target gene expression in breast cancer cells[J]. Nucleic Acids Res, 2019,47:2322-2335.doi: 10.1093/nar/gky1306. [13]Howlin J, Cirenajwis H, Lettiero B, et al. Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours[J]. Peer J, 2015,3:e788.doi: 10.7717/peerj.788. [14]Xu Y, Luo X, Fang Z, et al. Transcription coactivator Cited1 acts as an inducer of trophoblast-like state from mouse embryonic stem cells through the activation of BMP signaling[J]. Cell Death Dis, 2018,9:924-927. doi: 10.1038/s41419-018-0991-1. [15]Ono M, Lai KKY, Wu K, et al. Nuclear receptor/Wnt beta-catenin interactions are regulated via differential CBP/p300 coactivator usage[J]. PLoS One, 2018,13:e0200714.doi: 10.1371/journal.pone.0200714. |